Efficacy and safety of red ginseng on menopausal symptoms; A 12weeks, Randomized, Doubleblind, Placebo-Controlled Clinical Trial

Efficacy and safety of HarQ on menopausal symptoms; A 12week, Randomized, Doubleblind, Placebo-Controlled Clinical Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003879

Enrollment

120

Registered

2019-05-02

Start date

2018-12-12

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Efficacy and safety of HarQ on menopausal symptoms

A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial - Experimantal group Daily intake and ingestion method -Test foods: Take 2 tablets twice a day for 12 weeks -- placebo group Dai

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Women 40 to 65 years of age who are in the menopause (12 months or more) 2) Women with a KMI (kupperman index) score of 20 or higher 3) Women who have agreed to participate in this trial before the start of the clinical trial and who have written an informed consent form

Exclusion criteria

Exclusion criteria: 1) Women who have surgical or chemotherapy induced menopause 2) Women who have undergone hysterectomy 3) Women with a history of endometrial hyperplasia, endometrial cancer, breast disease, sex hormone related cancer 4) Patients with uncontrolled hypertension(160/100mmHg or higher, after 10 minutes of clinical test subjects) 5) A woman with a history of severe migraine within the past 1 year, diagnosed with thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or coronary angioplasty 6) A person whose ALT and AST exceed 3 times the normal upper limit 7) A person whose Creatinine exceed 2 times the normal upper limit 8) who are not considrered to be appropriate to particiapt on this study

Design outcomes

Primary

Measure	Time frame
Kupperman index	—

Secondary

Measure	Time frame
Climacteric symptoms questionnaire;Anthropometric markers;Safety markers	—

Countries

Korea, Republic of

Contacts

Public ContactJI YOUNG Lee

Konkuk University Medical Center

chess1@unitel.co.kr+82-2-2030-7643

Outcome results